| Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma EA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw, JM Versluis, ... Nature medicine 27 (2), 256-263, 2021 | 279 | 2021 |
| Comprehensive analysis of cutaneous and uveal melanoma liver metastases EP Hoefsmit, EA Rozeman, TM Van, P Dimitriadis, O Krijgsman, ... Journal for immunotherapy of cancer 8 (2), 2020 | 61 | 2020 |
| IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma ILM Reijers, D Rao, JM Versluis, AM Menzies, P Dimitriadis, MW Wouters, ... Journal of Experimental Medicine 220 (5), e20221952, 2023 | 43 | 2023 |
| Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors P Kaptein, C Jacoberger-Foissac, P Dimitriadis, P Voabil, M de Bruijn, ... Science translational medicine 14 (642), eabj9779, 2022 | 29 | 2022 |
| Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage … EA Rozeman, ILM Reijers, EP Hoefsmit, K Sikorska, O Krijgsman, ... Journal of Clinical Oncology 38 (15_suppl), 10015-10015, 2020 | 26 | 2020 |
| Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma I Fraterman, ILM Reijers, P Dimitriadis, A Broeks, M Gonzalez, ... Nature Medicine 29 (12), 3090-3099, 2023 | 20 | 2023 |
| The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the … EA Rozeman, JM Versluis, K Sikorska, R Lacroix, LG Grijpink-Ongering, ... Journal of Clinical Oncology 38 (15_suppl), 10021-10021, 2020 | 14 | 2020 |
| The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI)+ nivolumab (NIVO) in stage III melanoma. ILM Reijers, P Dimitriadis, EA Rozeman, O Krijgsman, S Cornelissen, ... Journal of Clinical Oncology 40 (16_suppl), 9539-9539, 2022 | 12 | 2022 |
| LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon … CU Blank, ILM Reijers, JM Versluis, AM Menzies, P Dimitriadis, ... Annals of Oncology 32, S1315, 2021 | 12 | 2021 |
| Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature … ILM Reijers, P Dimitriadis, EA Rozeman, JM Versluis, A Broeks, ... Journal of Clinical Oncology 38 (15_suppl), TPS10087-TPS10087, 2020 | 11 | 2020 |
| 36-months and 18-months relapse-free survival after (neo) adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients-update of the OpACIN and OpACIN-neo trials CU Blank, JM Versluis, EA Rozeman, AM Menzies, IL Reijers, ... Cancer Research 80 (16_Supplement), 3412-3412, 2020 | 10 | 2020 |
| IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 … EA Rozeman, JM Versluis, K Sikorska, EP Hoefsmit, P Dimitriadis, D Rao, ... Journal for Immunotherapy of Cancer 11 (7), 2023 | 9 | 2023 |
| Acidity‐mediated induction of FoxP3+ regulatory T cells D Rao, JA Stunnenberg, R Lacroix, P Dimitriadis, J Kaplon, F Verburg, ... European Journal of Immunology 53 (6), 2250258, 2023 | 8 | 2023 |
| The prognostic value of the interferon-gamma (IFNγ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy. JM Versluis, S Blankenstein, P Dimitriadis, J Sanders, W Hoefakker, ... Journal of Clinical Oncology 39 (15_suppl), 9579-9579, 2021 | 8 | 2021 |
| Inhibitor of apoptosis proteins antagonist induces T-cell proliferation after cross-presentation by dendritic cells EP Hoefsmit, PT van Royen, D Rao, JA Stunnenberg, P Dimitriadis, ... Cancer Immunology Research 11 (4), 450-465, 2023 | 6 | 2023 |
| L3 update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo) adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma … JM Versluis, EA Rozeman, AM Menzies, ILM Reijers, O Krijgsman, ... Journal for Immunotherapy of Cancer 8 (Suppl 2), 2020 | 5 | 2020 |
| MeVa2. 1. dOVA and MeVa2. 2. dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance D Rao, R Lacroix, A Rooker, T Gomes, JA Stunnenberg, M Valenti, ... Melanoma Research 33 (1), 12-26, 2023 | 4 | 2023 |
| Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma JM Versluis, SA Blankenstein, P Dimitriadis, JS Wilmott, R Elens, ... Journal for Immunotherapy of Cancer 12 (4), 2024 | 3 | 2024 |
| 6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab … P Dimitriadis, JJ Traets, R Saw, JM Versluis, T Pennington, E Kapiteijn, ... Immuno-Oncology and Technology 16, 2022 | 3 | 2022 |
| 797P Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI … ILM Reijers, AM Menzies, JM Versluis, P Dimitriadis, M Wouters, ... Annals of Oncology 33, S908-S909, 2022 | 3 | 2022 |
